Orexin
Receptors (Hypocretin Receptor) Antagonist Market, by Application
(Insomnia, Depression and Anxiety), by Dosage (5mg, 10mg, 15mg, and 20mg), and
by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Orexin (hypocretin) is a
neuropeptide produced by the lateral hypothalamus which regulates the
wakefulness, appetite, arousal and other habits. Orexin receptor antagonist is
the new class of drugs are used in the treatment of insomnia.
Suvorexant, is a dual orexin
receptor antagonist drug that blocks both pathways of OX1R and OX2R. It
develops sleep by the binding inhibition of orexin A and B, neuropeptides that
promote wakefulness. Approximately 70,000 orexin neurons are present in the
human brain, located in the perifornical lateral hypothalamus, which send
signals throughout the brain and spinal cord.
Global Orexin Receptors
Antagonist Market Drivers
The main growth driver for the
Orexin receptors antagonist market is the rising cases of insomnia. Insomnia is
caused by plenty of reasons such as anxiety, stress and depression. Lifestyle
problems can trigger insomnia like irregular sleeping patters, drinking alcohol
and smoking tobacco products before going to bed. Rising geriatric population,
increased stress levels in urban population also results into insomnia.
According to American Academy of Sleep Medicine AASM) as reported in 2014 insomnia affects 30% of adults, 15-20% have
short term insomnia and 10% of adults have chronic insomnia worldwide.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2522
Growing awareness about insomnia
and penetration of Belsomra into the market is expected to create more demand
in ORA market. Moreover, studies are
being conducted whether suvorexant can be used to treat depression and anxiety
so that the ORA market can witness further growth.
Global Orexin Receptors
Antagonist Market Restraints
Though suvorexant (Orexin
Receptors Antagonist) is the best drug available against insomnia, other
classes of drugs such as Benzodiazepines, Non-benzodiazepines, Antidepressants,
Melatonin Antagonist and medical devices like 2Breathe Sleep Inducer, Sleep Shepherd
Blue, Dreem Headband, Fisher Wallace Stimulator, SR1 Delta Sleeper can also be
used to treat insomnia which can negatively impede the market growth. Moreover,
in National Sleep Foundation (NSF) stated that in the year 2010 only 15% of
people were diagnosed with insomnia and only 6% receive the treatment for the
same. General negligence among the people about insomnia and the side effects
of drugs such as headache, sleepiness, next day drowsiness, weight loss
restricts the patients from using this medication.
Furthermore, clinical studies by
NCBI in 2015 showed the placebo treatment for insomnia is also effective for
the patients which hampers the growth of ORA market.
Global Orexin Receptors Antagonist
Market Regional analysis
North America is leading the
Orexin receptors antagonist market. Rising demand for insomnia treatment in the
U.S. and Canada coupled with increase in awareness, and high healthcare
spending are anticipated to drive the market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/orexin-receptors-hypocretin-receptor-antagonist-market-2522
Moreover, high prevalence of
insomnia among geriatric population in the U.S. are expected to increase the
demand. According to AASM in 2017 30-50% population of U.S. over the age of 60
has developed insomnia.
In Asia Pacific, China is
expected to show lucrative growth in the market owing to high prevalence of
insomnia. According to China National Knowledge Interne (CNKI) in 2017 15% of
China’s population is suffering from insomnia aging 43 and above From the
Journal of Community Medicine & Health Education as reported in 2017 in
India 72% of population above the age of 60 has insomnia. Asia Pacific is
anticipated to witness significant growth in near future because of shift-work
disorder and increasing stress level is expected to increase the number of
paitents in Asia Pacific. In addition, favorable reimbursement policies for
therapeutic products, strong product pipeline, and rising stress level are
other reasons contributing to the growth.
Global Orexin Receptors
Antagonist Market Key Players
Key competitors in the global
Orexin receptors antagonist market include Merck & Co. Inc., Sanofi,
Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P.,
Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, Vanda
Pharmaceuticals, and ECR Pharmaceuticals.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2522
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment